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rates for each country, as well as relative risk rates for
vaccinated children, were entered into the model. Pri-
mary research was used in Canada, Germany, and the
United Kingdom to establish incidence rates for the
model. Incidence data for other countries was obtained
from published studies. Relative risk data for vaccination
was obtained from the Northern California Kaiser Per-
manente Efficacy Study. The following “health states”
were considered in the model: well, meningitis, bactere-
mia, pneumonia, otitis media, sinusitis, and death. A de-
cision tree model was developed for each “health state”
in each country, to evaluate the direct and indirect cost of
illness. Each decision tree model was based on a local
clinical management analysis and resource valuation. The
Markov model was adapted to accommodate five dosing
schedules of PCV, based on the age of initial vaccination.
The expected utilization of PCV in all child groups was
incorporated in a net budgetary impact analysis. RE-
SULTS: Cost-effectiveness, measured as the incremental
cost-per-life-year gained, varied by country. PCV is a
cost-effective method of disease prevention when consid-
ering the savings in direct and indirect costs and the high
efficacy demonstrated in invasive disease. CONCLU-
SIONS: PCV should be supported by healthcare provid-
ers in the six countries because it is the only means of
pneumococcal disease prevention in a high-risk popula-
tion and it is cost-effective.
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OBJECTIVE: To estimate the clinical and economic ben-
efits of the pneumoccocal conjugate vaccine (PCV) in
preventing acute otitis media (AOM), tympanostomy, and
community-acquired pneumonia (CAP) (“study events”)
in young children. METHODS: We developed a model of
the incidence to age 10 years of study events in children
5 years of age, and used it to examine the benefits of
vaccination in a hypothetical cohort of 1000 children.
We estimated the cumulative incidence and medical-care
costs (discounted at 3%) of study events in the absence of
vaccination using data from a large health plan; indirect
costs were not considered. Among children vaccinated at
ages 2 years, vaccination was assumed to reduce the
annual number of cases of AOM by 7% to age 2 years,
by 9.6% between ages 2–5 years, and by 4.8% thereafter.
Among children vaccinated at ages 24–59 months, the
AOM rate was assumed to be reduced by 9.6% for 3
years, and by 4.8% thereafter. Vaccination was similarly
assumed to reduce the annual rate of tympanostomy and
CAP by 20% and 11% respectively to age 5 years among
children vaccinated at ages 2 years, and for 3 years for
those vaccinated at ages 24–59 months; thereafter, pro-
tective efficacy was assumed to be 10% and 5.5% respec-
tively. RESULTS: Vaccination would reduce the cumula-
tive incidence of AOM (to age 10 years) by 163–376 cases
per 1000 children, tympanostomy by 8–22 cases per 1000,
and CAP by 14–31 cases per 1000. Total cumulative dis-
counted medical-care costs would be reduced by $30,000–
$74,000 per 1000. CONCLUSION: Routine vaccination
of young children with PCV would reduce the incidence
and costs of AOM, tympanostomy, and CAP.
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OBJECTIVE: Although efavirenz has demonstrated excel-
lent efficacy in clinical trials and is less expensive than most
regimens, a full understanding of its economic impact re-
quires knowledge of the effect key parameters have on the
economic situation. In this study, the costs of managing
HIV treatment naïve patients with efavirenz compared to
indinavir were evaluated. METHODS: A model was devel-
oped to simulate the disease progression of a population of
HIV patients. Data from a clinical trial comparing two
nucleoside reverse transcriptase inhibitors plus efavirenz to
a similar regimen containing indinavir provided effective-
ness inputs to the model. These data along with the likeli-
hood of viral rebound over time were used to project the
long-term effectiveness of initial treatment with these regi-
mens. Cost estimates were developed from six all-payer
state discharge databases, fee schedules, survey data and
the literature for different disease states in the progression
of HIV. Costs are reported in 1998 US dollars. RESULTS:
Over the 24 week trial period, patients beginning treatment
with an efavirenz regimen were predicted to cost $2672 less
than those started on an indinavir regimen. Efavirenz is
forecast to maintain cost savings through year 6 ($11,015)
given its intention-to-treat response rate of 75%. Only if
this rate were 30% of the demonstrated rate would indi-
navir therapy be less expensive over the first 3.2 years fol-
lowing treatment initiation at which time efavirenz
achieves cost savings. Other factors such as the cost of indi-
navir therapy will be discussed. CONCLUSIONS: The re-
sults of our model suggest that the health benefits associ-
ated with efavirenz treatment are achieved at a cost savings
relative to indinavir treatment. These results were found to
be quite robust to variation in key parameters.
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